{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:28:27Z","timestamp":1787538507049,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00105-018-4124-7","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T11:39:51Z","timestamp":1517571591000},"page":"249-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aktuelle Aspekte in der Prognose des fortgeschrittenen Melanoms","Current aspects in the prognosis of advanced melanoma"],"prefix":"10.1007","volume":"69","author":[{"given":"J.","family":"Sirokay-Kohlmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"4124_CR1","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMra041245","volume":"351","author":"H Tsao","year":"2004","unstructured":"Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N\u00a0Engl J Med 351:998\u20131012. \n                    https:\/\/doi.org\/10.1056\/NEJMra041245","journal-title":"N Engl J Med"},{"key":"4124_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A et al (2017) Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer 83:247\u2013257. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.06.028","journal-title":"Eur J Cancer"},{"key":"4124_CR3","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong S\u2011J, Thompson JF, Atkins MB, Byrd DR et al (2009) Final version of 2009 AJCC melanoma staging and classification. J\u00a0Clin Oncol 27:6199\u20136206. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.23.4799","journal-title":"J Clin Oncol"},{"key":"4124_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI et al (2017) Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. Ca Cancer J Clin 67:472\u2013492. \n                    https:\/\/doi.org\/10.3322\/caac.21409","journal-title":"Ca Cancer J Clin"},{"key":"4124_CR5","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1200\/JCO.2009.27.1627","volume":"28","author":"CM Balch","year":"2010","unstructured":"Balch CM, Gershenwald JE, Soong S\u2011J, Thompson JF, Ding S, Byrd DR et al (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J\u00a0Clin Oncol 28:2452\u20132459. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.27.1627","journal-title":"J Clin Oncol"},{"key":"4124_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF et al (2014) Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N\u00a0Engl J Med 370:599\u2013609. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1310460","journal-title":"N Engl J Med"},{"key":"4124_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/bjd.13675","volume":"172","author":"M Sladden","year":"2015","unstructured":"Sladden M, Zagarella S, Popescu C, Bigby M (2015) No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the multicenter selective lymphadenectomy trial-I final report. Br J Dermatol 172:566\u2013571. \n                    https:\/\/doi.org\/10.1111\/bjd.13675","journal-title":"Br J Dermatol"},{"key":"4124_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","volume":"82","author":"NJ Ives","year":"2017","unstructured":"Ives NJ, Suciu S, Eggermont AMM, Kirkwood J, Lorigan P, Markovic SN et al (2017) Adjuvant interferon-alpha for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur J Cancer 82:171\u2013183. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.06.006","journal-title":"Eur J Cancer"},{"key":"4124_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008955.pub2","author":"S Mocellin","year":"2013","unstructured":"Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V (2013) Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.CD008955.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"4124_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejca.2017.09.014","volume":"86","author":"AMM Eggermont","year":"2017","unstructured":"Eggermont AMM, Dummer R (2017) The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. Eur J Cancer 86:101\u2013105. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.09.014","journal-title":"Eur J Cancer"},{"key":"4124_CR11","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J\u2011J, Dummer R, Wolchok JD, Schmidt H et al (2016) Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. N\u00a0Engl J Med 375:1845\u20131855. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1611299","journal-title":"N Engl J Med"},{"key":"4124_CR12","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL et\u00a0al (2017) Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. N\u00a0Engl J Med 377:1824\u20131835. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1709030","journal-title":"N Engl J Med"},{"key":"4124_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/978-3-319-22539-5_8","volume":"167","author":"MA Wilson","year":"2016","unstructured":"Wilson MA, Schuchter LM (2016) Chemotherapy for melanoma. Cancer Treat Res 167:209\u2013229. \n                    https:\/\/doi.org\/10.1007\/978-3-319-22539-5_8","journal-title":"Cancer Treat Res"},{"key":"4124_CR14","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et\u00a0al (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N\u00a0Engl J Med 372:2521\u20132532. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"4124_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J\u2011J, Cowey CL et al (2017) Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N\u00a0Engl J Med 377:1345\u20131356. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"key":"4124_CR16","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob J\u2011J, Mortier L et al (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a\u00a0multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390:1853\u20131862. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)31601-X","journal-title":"Lancet"},{"key":"4124_CR17","doi-asserted-by":"publisher","first-page":"9508","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","volume":"35","author":"GV Long","year":"2017","unstructured":"Long GV, Atkinson V, Menzies AM et al (2017) A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the anti-PD1 brain collaboration (ABC). J\u00a0Clin Oncol 35:9508. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.9508","journal-title":"J Clin Oncol"},{"key":"4124_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.hoc.2009.03.006","volume":"23","author":"AS Yang","year":"2009","unstructured":"Yang AS, Chapman PB (2009) The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am 23:583\u2013597. \n                    https:\/\/doi.org\/10.1016\/j.hoc.2009.03.006","journal-title":"Hematol Oncol Clin North Am"},{"key":"4124_CR19","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","volume":"17","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM et al (2016) Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a\u00a0randomised, double-blind, phase 3 trial. Lancet Oncol 17:1248\u20131260. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30122-X","journal-title":"Lancet Oncol"},{"key":"4124_CR20","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","volume":"28","author":"GV Long","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F et al (2017) Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a\u00a0phase 3 study. Ann Oncol 28:1631\u20131639. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx176","journal-title":"Ann Oncol"},{"issue":"suppl_5","key":"4124_CR21","doi-asserted-by":"publisher","first-page":"v428","DOI":"10.1093\/annonc\/mdx377","volume":"28","author":"R Dummer","year":"2017","unstructured":"Dummer R (2017) 1215O - results of COLUMBUS part 2: a phase 3 trial of Encorafenib (ENCO) plus Binimetinib (BINI) versus ENCO in BRAF-mutant melanoma. Ann Oncol 28(suppl_5):v428\u2013v448. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx377","journal-title":"Ann Oncol"},{"key":"4124_CR22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et\u00a0al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954. \n                    https:\/\/doi.org\/10.1038\/nature00766","journal-title":"Nature"},{"key":"4124_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1758834015616934","volume":"8","author":"Z Eroglu","year":"2016","unstructured":"Eroglu Z, Ribas A (2016) Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol 8:48\u201356. \n                    https:\/\/doi.org\/10.1177\/1758834015616934","journal-title":"Ther Adv Med Oncol"},{"key":"4124_CR24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob J\u2011J, Flaherty KT, Arance A et al (2017) Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18:863\u2013873. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30429-1","journal-title":"Lancet Oncol"},{"key":"4124_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14:463\u2013482. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2017.43","journal-title":"Nat Rev Clin Oncol"},{"key":"4124_CR26","doi-asserted-by":"publisher","first-page":"83155","DOI":"10.18632\/oncotarget.17950","volume":"8","author":"L Booth","year":"2017","unstructured":"Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P (2017) HDAC inhibitors enhance the immunotherapy response of melanoma cells. Oncotarget 8:83155\u201383170. \n                    https:\/\/doi.org\/10.18632\/oncotarget.17950","journal-title":"Oncotarget"},{"key":"4124_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-13-0458","volume":"4","author":"T Bald","year":"2014","unstructured":"Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P et al (2014) Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov 4:674\u2013687. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0458","journal-title":"Cancer Discov"},{"key":"4124_CR28","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O et al (2017) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170:1109\u20131119.e10. \n                    https:\/\/doi.org\/10.1016\/j.cell.2017.08.027","journal-title":"Cell"},{"key":"4124_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.immuni.2017.09.012","volume":"47","author":"N Glodde","year":"2017","unstructured":"Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O\u2019Donnell JS, Szczepanski S et al (2017) Reactive neutrophil responses dependent on the receptor tyrosine kinase c\u2011MET limit cancer immunotherapy. Immunity 47:789\u2013802.e9. \n                    https:\/\/doi.org\/10.1016\/j.immuni.2017.09.012","journal-title":"Immunity"},{"key":"4124_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejca.2017.01.011","volume":"76","author":"L Brochez","year":"2017","unstructured":"Brochez L, Chevolet I, Kruse V (2017) The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer 76:167\u2013182. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.01.011","journal-title":"Eur J Cancer"},{"key":"4124_CR31","doi-asserted-by":"publisher","first-page":"57845","DOI":"10.18632\/oncotarget.18471","volume":"8","author":"S Harada","year":"2017","unstructured":"Harada S, Arend R, Dai Q, Levesque JA, Winokur TS, Guo R et\u00a0al (2017) Implementation and utilization of the molecular tumor board to guide precision medicine. Oncotarget 8:57845\u201357854. \n                    https:\/\/doi.org\/10.18632\/oncotarget.18471","journal-title":"Oncotarget"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-018-4124-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4124-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4124-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T00:26:05Z","timestamp":1549067165000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-018-4124-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["4124"],"URL":"https:\/\/doi.org\/10.1007\/s00105-018-4124-7","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"assertion":[{"value":"2 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Sirokay-Kohlmeyer hat Honorare f\u00fcr Vortr\u00e4ge und Reiseunterst\u00fctzung durch die Firmen Roche, MSD, BMS und Novartis erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine vom Autor durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}